FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:1468-1470 May 14, 1998 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by The Trial to Reduce Alloimmunization to Platelets Study Group

To the Editor: The December 25 issue of the Journal presents two important prospective, controlled studies on the use of platelet transfusions.^1,2 Both studies, as commented on in an editorial in the same issue,³ could change transfusion policies. Leukocyte-depleted or ultraviolet B–irradiated pooled platelet products could replace single-donor–apheresis products because of their lower production costs, and the standard transfusion trigger could be lowered to 10x10⁹ platelets per liter. Though carefully designed, both studies in our view missed some important points.

Alloimmunization, the end point in the Trial to Reduce Alloimmunization to Platelets,¹ is only one aspect of a . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.